Overview

Anticoagulation on Demand in Paroxysmal Atrial Fibrillation After Percutaneous Coronary Intervention

Status:
Not yet recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
Preliminary experiences suggest that intermittent anticoagulation guided by continuous electrocardiographic monitoring can reduce the incidence of bleeding in patients with episodes of atrial fibrillation. Uncertainty about the potential implications of a strategy of intermittent anticoagulation after percutaneous coronary intervention exists. The investigators will perform a pilot randomized trial to evaluate the safety and efficacy of anticoagulation on demand in patients with paroxysmal atrial fibrillation after percutaneous coronary intervention.
Phase:
Phase 4
Details
Lead Sponsor:
University of Roma La Sapienza
Treatments:
Apixaban
Dabigatran
Edoxaban
Rivaroxaban